Expansion Synergies Cellecta's recent collaboration with Neoteryx to enable finger-prick blood-based comprehensive whole-genome expression profiling presents a cross-sell opportunity for integrated biomarker discovery services and remote sample collection workflows.

New profiling kits The launch of DriverMap EXP Human Genome-Wide 19K Dried Blood Microsample Profiling kit enables project scoping for customers needing high-throughput, minimal-volume RNA profiling from dried blood spots, opening up entry points in clinical research and translational studies.

Targeted screening edge Cellecta specializes in pooled shRNA and CRISPR libraries with NGS analysis, presenting upsell potential to customers pursuing functional target discovery, pathway mapping, and phenotypic screens in oncology, immunology, and rare disease areas.

Clinical translational focus Strategic partnerships like Tissue to Target and Cureline demonstrate a strengths in translational workflows; this positions Cellecta to offer end-to-end services from biospecimen handling to molecular analysis for pre-clinical and early clinical research programs.

Financials & scale With revenue in the 10–25 million range and a mid-sized team, there is room to propose scalable service bundles, volume-based pricing, and tiered offerings for mid-sized biotechs and academic groups expanding screening and profiling capabilities.